VacZine Analytics  
MarketVIEW: Chikungunya virus vaccines

Currently updating: September 2020

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection and during 2018/2019 a further 126 deaths were recorded across the PAHO region.

A number of potential CHIKV vaccine candidates (based on various approaches) are now in various stages of clinical development including those from Emergent BioSolutions, Themis Bio GmbH (Merck & Co) and Valneva Austria GmbH These candidates have received US and EU fast track regulatory designations underscoring their high medical need, and recently, the Coalition of Epidemic Preparedness Innovations (CEPI) has also disbursed funds to ongoing efforts. Regulators have approved new accelerated pathways to licensure based on immunogenicity (ICOP) rather than conducting a Phase III efficacy study. Once proven to be safe, a CHIKV vaccine could be available from 2022/23 onwards and used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent). The SARS-CoV-2 [COVID-19] pandemic will force a rethink on the optimum market positioning of a CHIKV vaccine.

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>250 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in First time and Repeat Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A newly engineered model for September 2020 now explores a mixed vaccine schedule market, impact of COVID-19 and brand new competitor entrance scenarios. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

THIS PRODUCT IS A SUMMARY PRESENTATION (>250 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV005 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2020 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains